bluebird bio (BLUE) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Business overview and product launches

• Three approved gene therapies: Lyfgenia (sickle cell), Zynteglo (beta thalassemia), Skysona (adrenoleukodystrophy), with sales ramping and a focus on profitability.

• 27 patient cell collections as of August 14, with a target of 85 for the year, indicating significant acceleration in launches.

• Each therapy priced around $3 million, with over $170 million in gross revenue potential projected for the last four and a half months of the year.

• 40 of the 58 remaining patient collections for the year are already scheduled, reflecting strong demand and high commitment.

• 71 Qualified Treatment Centers (QTCs) established, exceeding initial goals and supporting broad patient access.

Operational and market dynamics

• Manufacturing and delivery for Lyfgenia takes 85–105 days post-collection, with total process time of four to five months due to possible multiple collections.

• No urgency for rapid infusion as with CAR T therapies; process time is not seen as limiting uptake.

• QTCs initially start with one or two patients to establish process and reimbursement before scaling up.

• Focus has shifted from activating new QTCs to increasing patient throughput at existing centers.

• Insurance coverage for Lyfgenia now exceeds 200 million U.S. lives, with strong payer feedback and rapid reimbursement averaging two weeks.

Reimbursement and competitive positioning

• Outcomes-based agreements offered for Zynteglo and Lyfgenia, with rebates up to 80% if efficacy endpoints are not met.

• No ultimate denials for reimbursement across commercial and Medicaid payers for Zynteglo and Lyfgenia.

• Lyfgenia seen as having advantages over competitors due to QTC network size, long-term data, and process efficiencies.

• Fertility preservation offered for commercial insurance patients; efforts ongoing to expand access for government-insured patients.